Regeneron targets almost 50 patents in suit against Sandoz

Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

10 March 2026 The telehealth platform’s shares jumped more than 40% after the news that it will sell Ozempic and Wegovy—and no longer faces a lawsuit from the Danish pharma giant.

Americas

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

9 March 2026 Appeals court upholds lower court’s ruling, clarifying key legal questions concerning patent claims for blood‑testing devices.

Americas

Nomination call: Influential Women in IP list closes ahead of International Women’s Day

6 March 2026 With IWD approaching, WIPR urges practitioners to submit nominations for its Influential Women in IP list, recognising outstanding female leaders across the profession.

More features

GSK inks licensing deal for liver disease drug

Arnold & Porter adds tech litigator in San Francisco

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

UKIPO extends funding for specialist IP crime unit as counterfeit risks grow

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

Nomination call: Influential Women in IP list closes ahead of International Women’s Day

Abbott IP chief: ‘Firms without AI policies scare me’

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

Regeneron targets almost 50 patents in suit against Sandoz

More on this story

Editor's picks

Editor's picks

More features